Karl Ploessl
Overview
Explore the profile of Karl Ploessl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
940
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hong H, Wang G, Ploessl K, Zha Z, Zang J, Zhu Z, et al.
Nucl Med Biol
. 2021 Dec;
106-107:1-9.
PMID: 34952347
Purpose: Prostate-specific membrane antigen (PSMA) is an important biomarker for molecular imaging and a target for radionuclide therapy of prostate cancer. Recently, U.S. Food and Drug Administration (FDA) has approved...
12.
Xiao H, Choi S, Zhao R, Ploessl K, Alexoff D, Zhu L, et al.
ACS Med Chem Lett
. 2021 Jul;
12(7):1086-1092.
PMID: 34267878
[F]AV-45 (florbetapir f18, Amyvid) is an FDA-approved PET imaging agent targeting Aβ plaques in the brain for diagnosis of Alzheimer's disease (AD). Its metabolites led to a high background in...
13.
Zha Z, Choi S, Ploessl K, Alexoff D, Zhao R, Zhu L, et al.
Bioconjug Chem
. 2021 Apr;
32(5):1017-1026.
PMID: 33872489
Prostate-specific membrane antigen (PSMA)-targeted radioligands have played an increasing role in the diagnosis of prostate cancer. [Ga]Ga-P16-093 is a PSMA-targeting agent for positron emission tomography imaging, currently under a Phase...
14.
Hong H, Ploessl K, Zha Z, Wang H, Guo R, Xie Q, et al.
Appl Radiat Isot
. 2020 Dec;
169:109485.
PMID: 33360838
One of the commonly performed studies in nuclear medicine are bone scans with [Tc]Tc-methylene diphosphonate (MDP) for detecting various bone lesions, including cancer metastasis. The recent emergence of commercially available...
15.
Zhao R, Ploessl K, Zha Z, Choi S, Alexoff D, Zhu L, et al.
Mol Pharm
. 2020 Oct;
17(12):4589-4602.
PMID: 33108189
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells and therefore is an attractive target for prostate cancer diagnosis and radionuclide therapy. Recently, published results from clinical studies using...
16.
Zha Z, Wu Z, Choi S, Ploessl K, Smith M, Alexoff D, et al.
Mol Pharm
. 2020 Apr;
17(5):1674-1684.
PMID: 32251600
Positron emission tomography (PET) imaging using Ga-labeled bisphosphonates to target bone metastasis could be a valuable tool in cancer diagnosis and monitoring therapeutic treatment. A Ga labeled ligand, ,-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-,-diacetic acid...
17.
Zha Z, Ploessl K, Choi S, Alexoff D, Kung H
Nucl Med Biol
. 2020 Apr;
92:97-106.
PMID: 32245565
Introduction: Since the approval of three F labeled β-amyloid-targeting PET imaging agents, Amyvid (florbetapir f18, AV-45), Neuraceq (florbetaben f18, AV-1) and Vizamyl (flutemetamol f18, F-PIB), they have increasingly been employed...
18.
Yao X, Zha Z, Ploessl K, Choi S, Zhao R, Alexoff D, et al.
Bioorg Med Chem
. 2020 Feb;
28(5):115319.
PMID: 32001090
Radioligand therapy (RLT) using prostate-specific membrane antigen (PSMA) targeting ligands is an attractive option for the treatment of Prostate cancer (PCa) and its metastases. We report herein a series of...
19.
Zhao R, Zha Z, Yao X, Ploessl K, Choi S, Liu F, et al.
Nucl Med Biol
. 2019 Jul;
72-73:26-35.
PMID: 31330409
Objectives: Recently, a deuterated tracer, D6-[F]FP-(+)-DTBZ, 9-O-hexadeutero-3-[F]fluoropropoxyl-(+)-dihydrotetrabenazine ([F]9), targeting vesicular monoamine transporter 2 (VMAT2) in the central nervous system, was reported as a useful imaging agent for the diagnosis of...
20.
Yao X, Zha Z, Zhao R, Choi S, Ploessl K, Liu F, et al.
Nucl Med Biol
. 2019 Jun;
71:54-64.
PMID: 31152974
Introduction: Alzheimer's disease is a common neurodegenerative disease that is characterized by the presence of Aβ plaques in the brain. The FDA has approved the use of Amyvid (florbetapir f18,...